Daiichi Sankyo

  • Rigel and Daiichi-Sankyo have a long standing collaboration focused on discovering and developing specific MDM2 inhibitors involved in cancer.

  • Milademetan (DS 3032), a novel MDM2 inhibitor, is currently in Phase 1 development for various cancers.

  • Under the terms of the current agreement, Daiichi-Sankyo gave Rigel an upfront payment and will pay Rigel milestones over the life of the partnership. In addition, Rigel will receive royalties on any commercialized products to emerge from the collaboration.

  • To date, Rigel has received two milestone payments from Daiichi-Sankyo for the successful delivery of two potent and selective inhibitors of MDM2.